

Dr Clare van Halsema
North Manchester General Hospital

The effect of antiretroviral therapy on chest radiograph appearance in HIV-associated pulmonary tuberculosis

Clare van Halsema, Violet Chihota, Tom Gorsuch,
James Lewis, Elizabeth George, Katherine Fielding,
Gavin Churchyard, Alison Grant



LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



19th BHIVA, Manchester, April 2013

Background

- Clinical features of tuberculosis (TB) vary with the degree of HIV-associated immunosuppression (CD4 count)
- Positive sputum smears and lung cavitation are associated with TB transmission
- We have previously shown that combination antiretroviral therapy (cART) does not affect the proportion smear positive, independently of CD4 count¹
- The effect of cART on lung cavitation, independent of CD4 count, is unknown and relevant to TB control

Aim

- To examine the effect of cART on chest radiograph (CXR) appearance, particularly cavitation, as a marker of TB infectiousness



Setting

- TB case notification rates
2450 – 3000/100,000/year in 2008¹
- High HIV prevalence (around 29%²) on background of high TB incidence due to silicosis
- Thibela TB was a cluster-randomised trial of a mass TB prevention intervention
- TB screening and community-wide isoniazid preventive therapy were delivered in intervention clusters



THIBELA


Team up against **TB**

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Thibela TB study design

Baseline TB prevalence survey



Final TB prevalence survey

Enrolment in intervention clusters

Nine months to complete IPT in intervention clusters

12 months measurement period for primary outcome

Data extraction from medical records for all incident TB episodes in intervention and control clusters throughout study




Methods

- Cross-sectional analysis of TB episodes from 2004-9
- CXRs read by investigators masked to HIV and cART status
- Analysis included individuals with:
 - Known HIV and cART status
 - Pulmonary +/- disseminated or extrapulmonary disease
 - Sputum smear and/or *M. tuberculosis* culture positive
 - Available CXR within 2 months of TB treatment start
- Those on cART ≤ 90 days analysed separately in view of possible immune reconstitution inflammatory syndrome



Results: numbers included



Results: study group characteristics

Variable	Number ¹ (% of 495)
Male gender	481/494 (97%)
Median age	43 years (IQR 38, 48)
Living in hostel/informal housing	343/492 (71%)
First TB episode	318/487 (65%)
Sputum smear positive	370 (75%)
<i>M. tuberculosis</i> culture positive	385/423 (91%)




Results: HIV and cART status

Group	Number	Median CD4 count (cells/ μ l; IQR ¹ ; number with known CD4 count)
HIV-negative	156	-
HIV-positive not on cART	224	139* (76, 220; n=201)
HIV-positive on cART \leq 90 days	28	187 (90, 339; n=26)
HIV-positive on cART $>$ 90 days	87	219* (125, 333; n=80)
Total	495	149 (86, 263; n=307)

*Difference in CD4 distribution between those on cART $>$ 90 days versus not on cART: $p < 0.002$ by Kruskal-Wallis test



Results: sputum smear status



- Proportions smear-positive, regardless of cART status, varied non-linearly with CD4 count among HIV-positive individuals (χ^2 $p=0.01$)



Results: Bacillary density and cavitation


Cavitation	Smear grade: number (% of row total)					Total
	Negative	Scanty+	1+	2+	3+	
No	85 (31)	4 (2)	96 (35)	39 (14)	48 (18)	272 (100)
Yes	35 (16)	3 (1)	63 (29)	37 (17)	80 (37)	218 (100)
Total	120 (25)	7 (1)	159 (33)	76 (16)	128 (26)	490 (100)

- Cavitation is associated with higher sputum bacillary density (chi² p<0.001)




Results: lung cavitation

Proportion with lung cavitation by HIV and cART status



Comparing HIV-positive on cART >90 days vs. not on cART, odds ratio (OR) for cavitation 1.85 (1.11-3.09); $p=0.02$

Proportion with lung cavitation by CD4 category



Cavitation linearly associated with CD4 count: OR for cavitation 1.61 (1.27-2.06) for each increase in CD4 category ($p<0.001$)



Results: multivariable analysis

Model	Number of TB episodes included	OR for lung cavitation On cART >90 days vs. off cART	p-value ²
cART status (unadjusted)	311	1.85 (1.11-3.09)	0.02
cART status, adjusted for CD4	281	1.66 (0.95-2.91)	0.08
cART status, adjusted for CD4, age, episode type¹	259	1.50 (0.82-2.72)	0.19

- cART not associated with lung cavitation after adjustment in multivariable model



Study limitations

- Observational study with possible bias
 - HIV testing in those with more severe disease
 - cART used in group with specific characteristics
 - Missing data possibly associated with HIV-related outcomes
- Gold mining workforce with particular characteristics, eg silicosis, but internal comparisons still valid and relevant to other settings
- Some variation in timing of CD4, CXR, smear measurement could affect estimation of ORs



Conclusions

- High proportions smear positive in lowest CD4 stratum
- cART use was not associated with lung cavitation after adjustment for CD4 count
- Overall, cART is likely to increase infectiousness of TB through CD4 recovery
- This has implications for TB control in high HIV-prevalence areas, including nosocomial settings
- Data may be of use in modelling the impact of widespread cART use on TB transmission



Acknowledgements

Funding from:



British HIV Association
BHIVA

Gilead/BHIVA SpR research award 2009



THE COLT FOUNDATION
OCCUPATIONAL & ENVIRONMENTAL MEDICINE
The Foundation is a charity, registered No. 277189

The Colt Foundation, UK



Bill and Melinda Gates Foundation and CREATE
(primary funder for Thibela TB)



THIBELA
Team up against **TB**

Staff of Thibela TB and mine health services


LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



The effect of antiretroviral therapy on chest radiograph appearance in HIV-associated pulmonary tuberculosis


Clare van Halsema, Violet Chihota, Tom Gorsuch,
James Lewis, Elizabeth George, Katherine Fielding,
Gavin Churchyard, Alison Grant



The Pennine Acute Hospitals NHS Trust 

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



The logo of the British HIV Association (BHIVA) is a circular emblem with a complex, geometric design. It features a central circle surrounded by concentric rings of smaller circles and lines, creating a sunburst or molecular-like appearance. The logo is positioned behind the main title text.

British HIV Association
BHIVA

A light blue map of the United Kingdom is visible in the background. A red circular marker is placed on the map, indicating the location of Manchester in the north-western part of England. A thick vertical blue bar is on the left side of the slide.

19th Annual Conference of the British HIV Association (BHIVA)

16–19 April 2013

Manchester Central Convention Complex